



# I meeting del Laboratorio

Aperti a tutti


31 Maggio 2019, Ore 12.00

**Prof. ssa Elisabetta Verderio**  
(Dipart.Sc.Biol,Geol e Amb.)

## Transglutaminase in matrix remodelling and kidney fibro-

### ABSTRACT DELLA PRESENTAZIONE:

A dynamic network of molecules in our bodies, the extracellular matrix (ECM) continuously changes and remodels to maintain normal cell function. Without ECM, anchorage-dependent cells would die, but with too much fibrous matrix cells would not survive. This matrix repairs and heals, however if an injury persists it accumulates in vast amounts leading to extreme scarring and cell death. This talk will reveal what we have learned about a chief factor that allows the matrix to transform and re-invent itself, type 2-transglutaminase, and the importance



### BIOSKETCH PROF.SSA VERDERIO

Dr Elisabetta Verderio is a new Associate Professor of Biochemistry at the University of Bologna (UniBo), BIGEA, and a Reader/Associate Professor of Medical Biochemistry at Nottingham Trent University (NTU), College of Science and Technology. At NTU she is also Research Coordinator for Allied Health Professions (leading to research quality evaluation), co-lead for Diabetes and Chronic Disease, and Dean's representative in the doctoral school College Research Degrees Committee. As a non-clinical scientist, she obtained her first permanent academic post of Lecturer/Senior Lecturer at NTU in 2004, and with that she established an independent research group. Since then she has conducted extensive research on the patho-physiology of the transglutaminase family of enzymes in models of chronic kidney disease (CKD) with an interest in cell-matrix molecular dynamics, also encompassing other areas (wound healing, fibrosis, cancer). With colleagues at the University of Sheffield, she has pioneered the application of next generation SWATH™-Mass spectrometry for profiling CKD-proteome models. Recently, her group have focused on the isolation and characterisation of nano-sized extracellular vesicles from cells and biological fluids with a view of applying exosome proteomics to CKD patients' stratification. Through the years her work has been mainly funded by the Wellcome Trust and Kidney Research UK, and more recently by UCB pharmaceuticals.

**Policlinico S.Orsola-Malpighi- Padiglione 25, piano terra-Aula Placitelli**